103258-38-4

Basic information

• Product Name: Benzamide, N,N-diethyl-2-(hydroxymethyl)-
• CAS NO: 103258-38-4
• Molecular Formula: C12H17NO2
• Molecular Weight: 207.272
• Mol File: 103258-38-4.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Benzamide, N,N-diethyl-2-(hydroxymethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, N,N-diethyl-2-(hydroxymethyl)-(103258-38-4)
• EPA Substance Registry System: Benzamide, N,N-diethyl-2-(hydroxymethyl)-(103258-38-4)

Safety Data

• Hazardous Substances Data: 103258-38-4(Hazardous Substances Data)

Upstream product

• 611-74-5 N,N-dimethylbenzamide 
• 88-10-8 N,N-diethylcarbamyl chloride 
• 127787-04-6 N-(Bis-trimethylsilanyl-methyl)-N-methyl-benzamide 
• 76041-86-6 2-bromo-N,N-diethylbenzamide 
• 87-41-2 2-benzofuran-1(3H)-one 
• 660-68-4 diethyl amine hydrochloride 
• 77420-44-1 2-formyl-N,N-diethyl-1-benzamide 
• 553-86-6 benzofuran-2(3H)-one 
• 109-89-7 diethylamine 
• 127787-11-5 N-(Bis-trimethylsilanyl-methyl)-N',N'-diethyl-N-methyl-phthalamide 
• 2728-04-3 N,N-diethyl-ortho-toluamide 

Downstream Products

• 952493-89-9 N,N-diethyl-2-[(1-hydroxycyclobutyl)-(5-iodoimidazol-1-yl)methyl]benzamide 
• 952493-92-4 N,N-diethyl-2-[2-hydroxy-1-(5-iodoimidazol-1-yl)-2-methylpropyl]benzamide 
• 952493-88-8 N,N-diethyl-2-(5-iodoimidazol-1-ylmethyl)benzamide 
• 1428732-54-0 2-((di-tert-butylphosphino)methyl)-N,N-diethybenzamide hydrobromide 
• 220208-86-6 (S)-N,N-diethyl-o-(2,2-dimethyl-1-hydroxy-3-butenyl)benzamide 
• 342012-01-5 2-chloromethyl-N,N-diethylbenzamide 
• 220208-73-1 N,N-diethyl-o-allyloxymethylbenzamide 
• 220208-81-1 N,N-diethyl-o-(3-methyl-2-butenyloxymethyl)benzamide 
• 103258-32-8 N,N-diethyl-2-(bromomethyl)benzamide 

Relevant articles and documents

Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors

CYP11B2, the aldosterone synthase, and CYP11B1, the cortisol synthase, are two highly homologous enzymes implicated in a range of cardiovascular and metabolic diseases. We have previously reported the discovery of LCI699, a dual CYP11B2 and CYP11B1 inhibi

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I):said compound is inhibitor of aldosterone synthase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, cardiac fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.

Sparteine-mediated enantioselective [2,3]-Wittig rearrangement of allyl ortho-substituted benzyl ethers and ortho-substituted benzyl prenyl ethers

The (-)-sparteine-mediated enantioselective [2,3]-Wittig rearrangement of N,N-dialkyl-o-allyloxymethylbenzamides and o-substituted benzyl prenyl ethers has been investigated. Enantiomeric excess up to 60% was observed as for the reaction with N,N-diethyl-o-allyloxymetylbenzamide. From the mechanistic investigations, it was suggested that the stereoinformation was introduced at the deprotonation step. Substoichiometric amount of (-)- sparteine (0.2 equiv.) did not decrease the enantioselectivity. Introduction of functional groups other than carbamoyl group did not enhance the enantioselectivity in this rearrangement.